keyword
MENU ▼
Read by QxMD icon Read
search

Degludec

keyword
https://www.readbyqxmd.com/read/28417535/rates-of-hypoglycaemia-are-lower-in-patients-treated-with-insulin-degludec-liraglutide-ideglira-than-with-ideg-or-insulin-glargine-regardless-of-the-hypoglycaemia-definition-used
#1
P Norwood, R Chen, E Jaeckel, I Lingvay, H Jarlov, L Lehmann, S Heller
AIMS: The rates of hypoglycaemia reported in clinical trials are affected by the definitions of hypoglycaemia used. This post-hoc analysis took data from two trials comparing the once-daily, fixed ratio combination of insulin degludec/liraglutide (IDegLira) with basal insulin regimens, and re-analysed these data using alternative hypoglycaemia definitions and stratified outcomes by dosing time and baseline characteristics. MATERIALS AND METHODS: Post hoc analyses of the DUAL I (patients uncontrolled on oral antidiabetic drugs) and DUAL V (patients uncontrolled on insulin glargine (IGlar) U100) trials were carried out using different definitions of hypoglycaemia and by whether treatments were administered in the AM or PM...
April 17, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28368217/long-acting-insulin-allergy-in-a-diabetic-child
#2
Carla Mastrorilli, Laura Rizzuti, Antonina Marta Cangelosi, Brunella Iovane, Giovanni Chiari, Carlo Caffarelli
Insulin allergy has been uncommon since the introduction of human recombinant insulin preparations; the prevalence is 2.4%. Insulin injection could elicit immediate reactions, which are usually induced by an IgE-mediated mechanism, within the first hour after drug administration. In the present study, we describe the case of a child who experienced immediate urticaria after long-acting insulin injection. A 9-year-old girl affected by type I diabetes mellitus referred a history of three episodes of urticaria 30 min after insulin subcutaneous injection...
April 1, 2017: International Journal of Immunopathology and Pharmacology
https://www.readbyqxmd.com/read/28349716/fixed-ratio-combination-therapy-with-glp-1-receptor-agonist-liraglutide-and-insulin-degludec-in-people-with-type-2-diabetes
#3
Lauge Østergaard, Christian Seerup Frandsen, Thomas Fremming Dejgaard, Sten Madsbad
A fixed combination of basal insulin degludec and glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide (IDegLira; 50 units degludec/1.8 mg liraglutide) has been developed as a once daily injection for the treatment of type 2 diabetes (T2D). In the phase 3a trial programme "Dual action of liraglutide and insulin degludec in type 2 diabetes" (DUAL™), five trials of 26 weeks duration and one trial of 32 weeks duration have evaluated the efficacy and safety of IDegLira compared with administration of insulin degludec, insulin glargine, liraglutide alone or placebo...
March 28, 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28332144/efficacy-and-safety-of-ideglira-in-participants-with-type-2-diabetes-in-india-uncontrolled-on-oral-antidiabetic-drugs-and-basal-insulin-data-from-the-dual-clinical-trial-program
#4
Kamlesh Khunti, Viswanathan Mohan, Sunil M Jain, Trine Welløv Boesgaard, Kamilla Begtrup, Bipin Sethi
INTRODUCTION: The efficacy and safety of insulin degludec/liraglutide (IDegLira) has been evaluated in the Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes (DUAL) phase 3 clinical trial program. In this post hoc analysis, we compared the efficacy and safety of IDegLira in the Indian subpopulation with the results from the global trial population of DUAL trials. The analysis includes participants uncontrolled on oral antidiabetic drugs (OADs) in DUAL I and DUAL IV and participants uncontrolled on basal insulin and OADs in DUAL II...
March 22, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28295934/insulin-degludec-lower-day-to-day-and-within-day-variability-in-pharmacodynamic-response-compared-to-insulin-glargine-u300-in-type-1-diabetes
#5
Tim Heise, Marianne Nørskov, Leszek Nosek, Kadriye Kaplan, Susanne Famulla, Hanne L Haahr
AIM: To compare day-to-day and within-day variability in glucose-lowering effect between insulin degludec (IDeg) and insulin glargine 300 U/mL (IGlar-U300) in type 1 diabetes. MATERIALS AND METHODS: In this double-blind, crossover study, patients were randomly assigned to 0.4 U/kg of IDeg or IGlar-U300 once-daily for two treatment periods lasting 12 days each. Pharmacodynamic parameters were assessed at steady state from glucose infusion rate profiles of three 24h euglycaemic glucose clamps (Days 6, 9 and 12) during each treatment period...
March 14, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28294641/evaluation-of-the-long-term-cost-effectiveness-of-ideglira-versus-liraglutide-added-to-basal-insulin-for-patients-with-type-2-diabetes-failing-to-achieve-glycemic-control-on-basal-insulin-in-the-usa
#6
B Hunt, M Mocarski, W J Valentine, J Langer
BACKGROUND AND AIMS: IDegLira, a fixed ratio combination of insulin degludec and glucagon-like peptide-1 receptor agonist liraglutide, utilizes the complementary mechanisms of action of these two agents to improve glycemic control with low risk of hypoglycemia and avoidance of weight gain. The aim of the present analysis was to assess the long-term cost-effectiveness of IDegLira vs liraglutide added to basal insulin, for patients with type 2 diabetes not achieving glycemic control on basal insulin in the US setting...
March 3, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28282219/a-fixed-ratio-combination-of-insulin-degludec-and-liraglutide-ideglira-reduces-glycemic-fluctuation-and-brings-more-patients-with-type-2-diabetes-within-blood-glucose-target-ranges
#7
Allen B King, Athena Philis-Tsimikas, Eric S Kilpatrick, Irene H Langbakke, Kamilla Begtrup, Tina Vilsbøll
BACKGROUND: Reducing glycemic fluctuation is important for optimal diabetes management. This post hoc analysis examined glycemic fluctuations and the proportion of subjects achieving recommended blood glucose targets with the fixed ratio combination of insulin degludec and liraglutide (IDegLira) compared to insulin degludec (IDeg) and liraglutide alone. METHODS: We analyzed nine-point self-monitored blood glucose (SMBG) profiles from two randomized trials involving IDegLira in patients with type 2 diabetes (T2D), and continuous glucose monitoring (CGM) data from a subset of patients in one of these trials to assess glycemic fluctuation and day-to-day variability...
April 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28277867/the-role-of-the-new-basal-insulin-analogs-in-addressing-unmet-clinical-needs-in-people-with-type-1-and-type-2-diabetes
#8
Rosemarie Lajara, Eda Cengiz, Robert J Tanenberg
BACKGROUND: Despite improvements in anti-hyperglycemic therapies, there are many unmet clinical needs that hinder successful glycemic control in people being treated with current basal insulin analogs. OBJECTIVE: This paper reviews the unmet needs associated with current basal insulin therapy and describes the most recent basal insulins for the treatment of diabetes. METHODS: PubMed was searched for articles on basal insulin analogs published between 2000 and April 2016...
March 24, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28275957/erratum-to-auxiliendo-primum-non-nocere-a-preliminary-view-of-the-devote-trial-comparing-cardiovascular-safety-of-insulin-degludec-versus-insulin-glargine-in-type-2-diabetes
#9
Sanjay Kalra
No abstract text is available yet for this article.
April 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28250698/pharmaceutical-approval-update
#10
Mary Choy
Insulin degludec/liraglutide (Xultophy 100/3.6) for type-2 diabetes; rucaparib (Rubraca) for the treatment of deleterious BRCA mutation-associated ovarian cancer; and nusinersen (Spinraza) for the treatment of spinal muscular atrophy.
March 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28242866/cross-over-study-comparing-postprandial-glycemic-increase-after-addition-of-a-fixed-dose-mitiglinide-voglibose-combination-or-a-dipeptidyl-peptidase-4-inhibitor-to-basal-insulin-therapy-in-patients-with-type-2-diabetes-mellitus
#11
Noriko Ihana-Sugiyama, Ritsuko Yamamoto-Honda, Takehiro Sugiyama, Tetsuro Tsujimoto, Masafumi Kakei, Mitsuhiko Noda
BACKGROUND Although the efficacy of combination therapy consisting of basal insulin and oral hypoglycemic agents (OHAs) has been shown, which OHAs are the most efficient remains unclear. MATERIAL AND METHODS Five patients with type 2 diabetes were enrolled and treated with insulin degludec and metformin as a basal therapy. The patients were randomized in a cross-over fashion to receive a combination of mitiglinide (10 mg) and voglibose (0.2 mg) (M+V) 3 times daily or linagliptin (5 mg) (L) once daily for 8 weeks...
February 28, 2017: Medical Science Monitor Basic Research
https://www.readbyqxmd.com/read/28236272/a-large-difference-in-dose-timing-of-basal-insulin-introduces-risk-of-hypoglycemia-and-overweight-a-cross-sectional-study
#12
Akiko Nishimura, Shin-Ichi Harashima, Haruna Fukushige, Yu Wang, Yanyan Liu, Kiminori Hosoda, Nobuya Inagaki
INTRODUCTION: Basal insulin should be injected at the same time each day, but people with diabetes sometimes mistime their injections. It is not known whether irregular daily dose timing affects diabetes-related factors. We report here our evaluation of the effects of deviations from a regular dosing schedule on glycemic control and hypoglycemia on patients treated with long-acting insulin (insulin glargine U100). We also consider the effects of ultra-long-acting insulin (insulin degludec) in this context...
April 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28220460/glycemic-control-in-a-real-life-setting-in-patients-with-type-2-diabetes-treated-with-ideglira-at-a-single-swiss-center
#13
Daniela Sofra
INTRODUCTION: The aim of the present study was to describe clinical outcomes in a real-world population of Swiss patients with long-standing, poorly controlled type 2 diabetes after switching to IDegLira [a combination of insulin degludec (IDeg) and liraglutide (Lira)]. METHODS: This was a prospective, open-label, single-center observational follow-up at the Cabinet Medical de Diabétologie, Lausanne, Switzerland, of 61 patients [HbA1c 9.2% (77 mmol/mol) and 56...
April 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28210866/cost-effectiveness-of-insulin-degludec-versus-insulin-glargine-in-adults-with-type-1-and-type-2-diabetes-mellitus
#14
Marc Evans, Barrie Chubb, Jens Gundgaard
INTRODUCTION: To estimate the cost-effectiveness of insulin degludec (IDeg) versus insulin glargine U100 (IGlar U100) and new-to-market basal insulin analogues in patients with diabetes in order to aid decision-making in a complex basal insulin market. METHODS: A simple, short-term model was used to evaluate the costs and effects of treatment with IDeg versus IGlar U100 over a 12-month period in patients with type 1 (T1DM) and type 2 diabetes (T2DM) from the perspective of the UK National Health Service...
April 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28197833/auxiliendo-primum-non-nocere-a-preliminary-view-of-the-devote-trial-comparing-cardiovascular-safety-of-insulin-degludec-versus-insulin-glargine-in-type-2-diabetes
#15
Sanjay Kalra
A demonstration of cardiovascular safety is mandatory for all newly developed glucose-lowering agents, including insulin analogues. The vascular benefit of insulin is evident from the Diabetes Control and Complication Trial (DCCT) and United Kingdom Prospective Diabetes Study (UKPDS), and the cardiovascular safety of insulin glargine has been demonstrated in individuals with newly diagnosed diabetes or prediabetes in the ORIGIN trial (Outcome Reduction with an Initial Glargine Intervention). The top-line results of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs...
April 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28187863/a-review-of-the-clinical-efficacy-and-safety-of-insulin-degludec-and-glargine-300-u-ml-in-the-treatment-of-diabetes-mellitus
#16
REVIEW
Vincent C Woo
PURPOSE: The treatment of type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) using insulin is not ideal at this time. Despite advances made with basal insulin analogues, many individuals achieve less than optimal glycemic control or are at risk for hypoglycemia. Currently available basal insulin analogues do not deliver steady, peakless, continuous insulin for >24 hours and are associated with adverse events, including hypoglycemia. The objective of this paper was to review the clinical efficacy and safety of upcoming long-acting insulin analogues such as insulin degludec and insulin glargine 300 U/mL (Gla-300)...
February 7, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28150516/efficacy-and-safety-of-fixed-ratio-combination-of-insulin-degludec-and-liraglutide-ideglira-for-the-treatment-of-type-2-diabetes
#17
REVIEW
Louise Vedtofte, Filip K Knop, Tina Vilsbøll
Type 2 diabetes (T2D) is a progressive disease with increasing prevalence in most countries. The majority of patients with T2D have inadequate glycaemic control, which increases the risk of diabetic complications later in life. New therapies with improved safety profiles are required to tackle the progressive nature of T2D. Areas covered: The efficacy and safety profile of IDegLira - a once-daily, fixed-ratio combination of insulin degludec and liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), for the treatment of T2D - has been extensively evaluated...
March 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28124817/safety-and-efficacy-of-ideglira-titrated-once-weekly-versus-twice-weekly-in-patients-with-type-2-diabetes-uncontrolled-on-oral-antidiabetic-drugs-dual-vi-randomized-clinical-trial
#18
Stewart B Harris, Győző Kocsis, Rudolf Prager, Terry Ridge, Keval Chandarana, Natalie Halladin, Serge Jabbour
OBJECTIVE: To compare the safety and efficacy of a simpler titration algorithm for insulin degludec/liraglutide (IDegLira) with that used in previous DUAL trials in insulin-naïve patients with type 2 diabetes. RESEARCH DESIGN AND METHODS This 32-week, open-label, non-inferiority trial randomized adults with type 2 diabetes uncontrolled on metformin ± pioglitazone to receive IDegLira, titrated either once weekly based on the mean of two pre-breakfast plasma glucose (PG) readings (n = 210), or twice weekly based on the mean of three pre-breakfast PG readings (n = 210)...
January 26, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28091878/insulin-degludec-in-clinical-practice-a-review-of-japanese-real-world-data
#19
Kohei Kaku, Michael Lyng Wolden, Jacob Hyllested-Winge, Emil Nørtoft
INTRODUCTION: In this literature review we evaluated the real-world clinical effectiveness of switching Japanese diabetic patients from their current insulin regimen to insulin degludec (IDeg). METHODS: Studies were identified from Japanese Diabetes Society (JDS) abstracts (2014-2015) and PubMed (2012 onwards). Inclusion criteria were: Japanese population, >15 participants, and studies switching patients from basal or basal-bolus insulin regimens to IDeg. Randomized controlled trials and case reports were excluded...
February 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28077204/review-of-the-next-generation-of-long-acting-basal-insulins-insulin-degludec-and-insulin-glargine
#20
Matthew Stailey, Susan E Conway
Older adults are at an increased risk of developing type 2 diabetes mellitus (T2DM). Although oral agents (i.e., metformin) are the preferred first-line therapy, older adults often eventually require the addition of insulin to control their blood glucose. Long-acting insulin analogues are the preferred insulin products for older adults with T2DM. Insulin degludec and insulin glargine U-300 are both new generation long-acting insulins. When compared with the standard of care, long-acting insulin product insulin glargine U-100, insulin degludec, and insulin glargine U-300 had similar glucose-lowering effects, longer half-lives and durations of action, and a more even distribution over a 24-hour period...
January 1, 2017: Consultant Pharmacist: the Journal of the American Society of Consultant Pharmacists
keyword
keyword
10126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"